CKD-Anaemia on-demand webinar

This programme has been supported and funded by Astellas Pharma.

Faculty
MUSTAFA ARICI, MD FERA, Hacettepe University Faculty of Medicine, Department of Nephrology, Ankara, Turkey
JONATHAN BARRATT, PHD FRCP, John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom
DANILO FLISER, MD, Saarland University Medical Center, Internal Medicine IV, Nephrology and Hypertension, Homburg, Germany

Learning objectives

After completing this activity, participants should be able to:

• Provide an overview of the epidemiology of anaemia of CKD

• Identify drivers of patients’ and physicians’ treatment preferences

• Describe current treatment options and unmet needs in anaemia of CKD

• Evaluate the impact of anaemia on cardiovascular risk in patients with CKD

• Analyse different available treatment options, particularly with regards to the use of HIF-PH inhibitors versus standard of care

• Critically assess the latest clinical data pertaining to the treatment of anaemia in CKD, including the use of decision-making tools

DISCLAIMER
The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional licence, experience and knowledge of the individual patient.

For full prescribing information, including indications, contraindications, warnings, precautions and adverse events, please refer to the approved product labelling. Please note that products may have different product labelling according to geographical location. Within Europe, full prescribing information is available from the European Medicines Agency (EMA – www.ema.europa.eu).
Release Date: 04 December 2022
Expiration Date: 04 December 2023